Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

733 ARTÍCULOS , VIENDO DEL 556 AL 570

Comparative assessment of donepezil memantine and sodium oligomannate on cognitive decline and neuroinflammation in early Alzheimer's disease

Deng X, Zeng Y, Ding D.

Pak J Pharm Sci. 2026 Apr;39(4):944-957. doi: 10.36721/PJPS.2026.39.4.REG.15270.1.

Improvement of age-related neurocognitive disorders by Ginkgo biloba extract: neuroprotection in focus

Eckert A, Georgescu D, Seifritz E, Müller WE.

Int J Psychiatry Clin Pract. 2026 Jun;30(2):115-128. doi: 10.1080/13651501.2026.2617217. Epub 2026 Jan 23.

Astrocyte-derived exosomes in cognitive recovery: A comparative assessment of neurobehavioral, molecular, and electrophysiological dimensions

Hoveizi E, Karimi A, Khajehpour L, Ghotbeddin Z, Pyecroft S.

Behav Brain Res. 2026 Jun 5;507:116196. doi: 10.1016/j.bbr.2026.116196. Epub 2026 Mar 28.

Beneficial Effects of Olive Oil and the Mediterranean Diet on Alzheimer's Disease and Vascular Dementia: A Review

González-Cidad A, García-Moncó JC, Román GC.

Medicina (Kaunas). 2026 Apr 4;62(4):696. doi: 10.3390/medicina62040696.

Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer's disease: A systematic review and meta-analysis

Javaid H, Jha A, Cheema U, Noor M, Cheema S, Arfan M, Aqeel M, Habib E, Saddique MN, Qadri M, Shamoon S.

Neurol Sci. 2026 Jan 29;47(2):208. doi: 10.1007/s10072-025-08649-y.

Cumulative cognitive benefits and brain volume change with anti-amyloid therapies for Alzheimer's disease

Lin YH, Hsu TW, Kao YC, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Hsu CW, Yang FC, Tsai CK, Yu CL, Liang CS, Tu YK.

J Neurol Neurosurg Psychiatry. 2026 May 14;97(6):497-504. doi: 10.1136/jnnp-2025-336691.

The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials

O'Mara A, Mody BP, Mammi M, Simjian T, Ghattas K, Kaliki S, Le NPM, Liew A, Migliore M, Mekary RA.

Neurol Sci. 2026 Jan 12;47(1):149. doi: 10.1007/s10072-025-08602-z.

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease

Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C, Gonzalez-Lorenzo M, Vignatelli L, Filippini G, Richard E.

Cochrane Database Syst Rev. 2026 Apr 16;4(4):CD016297. doi: 10.1002/14651858.CD016297.

A meta-analysis of the effect of non-invasive neuromodulation techniques on improving cognitive function in patients with Alzheimer's disease

Wen J, Li M, Xu J, Sun Y, Chen X, Mao Z.

Neurol Sci. 2026 Mar 5;47(4):320. doi: 10.1007/s10072-026-08852-5.

Digital Cognitive Rehabilitation Platforms for Older Adults in Portugal: A Systematic Review

Raposo A, Gonçalves F, Leonido L, Mendes L.

Int J Environ Res Public Health. 2026 Apr 1;23(4):453. doi: 10.3390/ijerph23040453.

Alzheimer's disease and dementia care in Nigeria: Challenges, realities, and the call for a national strategy

Ndionuka IB.

J Alzheimers Dis. 2026 Apr;110(4):1629-1631. doi: 10.1177/13872877261424254. Epub 2026 Feb 26.

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial

Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG.

Neurol Clin Pract. 2026 Jun;16(3):e200621. doi: 10.1212/CPJ.0000000000200621. Epub 2026 May 13.

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, Johannsen P, Wichmann CA, Abschneider RM, Leon T, Feldman HH.

Lancet. 2026 May 30;407(10544):2167-2179. doi: 10.1016/S0140-6736(26)00459-9. Epub 2026 Mar 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias